Investigative Urology

Taxol and Taurine Protect the Renal Tissue of Rats after Unilateral Ureteral Obstruction: A Stereological Survey

Saied Karbalay-Doust, Ali Noorafshan, Seyed-Mohammad Pourshahid
Histomorphometry and Stereology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Purpose: Blockage of the urinary tract induces changes in renal structure including tubular dilatation or atrophy, tubular cell death, inflammatory processes, and progressive interstitial fibrosis with the loss of renal parenchyma. The present study was conducted to survey the protective effects of Taxol and taurine on the renal structure after unilateral ureteral obstruction (UUO).

Materials and Methods: UUO was induced in three groups of rats (n=6) who then received distilled water, Taxol (0.3 mg/kg/d), or taurine (7.5 mg/kg/d). Stereological methods were used to gather quantitative as well as comparative data.

Results: Less than -8% of the volume of the glomeruli, proximal convoluted tubules (PCT), distal convoluted tubules (DCT), Henle's loop, and collecting ducts were preserved after UUO. After treatment of the UUO rats with Taxol, between -32% and 88% of the parameters mentioned above remained intact, and after treatment of the UUO rats with taurine, between -16% and 46% of the parameters remained intact (p < 0.01). Compared with the untreated UUO animals, the volume of necrotic and fibrotic tissues decreased -53% and -63% in the UUO rats treated with Taxol and taurine, respectively (p < 0.01). Less than -3% of the lengths of the renal tubules (PCT, DCT, Henle's loop, and collecting) were preserved in the UUO rats. After treatment with Taxol and taurine, -61% to 70% and -43% to 53% of the length of the renal tubules were preserved, respectively (p < 0.01).

Conclusions: Taurine and Taxol are effective in preventing some structural renal damage in a direct ureteral obstruction model. Taxol was more effective in renal protection.

Key Words: Kidney; Stereology; Taurine; Taxol; Ureteral obstruction

INTRODUCTION

Chronic kidney diseases, which lead to end-stage kidney failure, are associated with changes in kidney structure and fibrosis regardless of the underlying cause [1]. Urinary tract obstruction is characterized by tubular atrophy or dilatation, tubular cell death by apoptosis and necrosis, interstitial leukocyte infiltration, and increased interstitial matrix deposition. [1]. Such an obstruction might be observed after benign prostatic hyperplasia; renal, ureteral, or bladder calculi; urethral stricture; and neoplasm of the bladder, prostate, or urethra [1]. The hydrostatic pressure, which is the result of the blockage, initiates renal injuries. The injuries are characterized by tubular dilatation or atrophy, inflammatory infiltration of leucocytes, fibroblast activation, proliferation, increase in matrix proteins, and progressive interstitial fibrosis with the loss of renal parenchyma. Unilateral ureteral obstruction (UOO) is an experimental rat model of renal injury that imitates the process of obstructive nephropathy in an accelerated manner [1]. Evidence supports a key role of the inflammatory process in the renal structural changes that occur after uroraphy [2].

Taurine (2-aminoethanesulfonic acid) is an organic acid and a major component of the bile. Taurine is a derivative of the sulfur-containing amino acid cysteine. Taurine has
been shown to have beneficial effects on the renal fibrosis that occurs after cisplatin-induced injuries, diabetic nephropathy, and age-related renal changes [1,3,4]. Taurine has also been associated with a reduction in oxidant levels in diabetic nephropathy [4]. It also plays an important role in some biochemical and physiological processes in the kidney. In a review, Chesney et al. [2] described the renal-taurine interactions related to ion reabsorption, renal blood flow, renal vascular endothelial function, and antioxidant properties (especially in the glomerulus) [5]. In addition, it has been reported that taurine plays a major role in the renal cell cycle as well as in apoptosis and also functions as an osmolyte during the stress response. Taurine has been shown to play an important role in four different forms of kidney diseases: glomerulonephritis [6], diabetic nephropathy, chronic renal failure [7], and acute kidney injury [8].

Taxol (paclitaxel) is a mitotic inhibitor that is used in cancer chemotherapy. Paclitaxel stabilizes microtubules and as a result interferes with the normal breakdown of the microtubules during cell division. Sun et al. [9] and Zhang et al. [10] have reported that paclitaxel ameliorates fibrosis in the UUO rat kidney model. In addition, Sommardahl et al. [11] showed the efficacy of Taxol in the mouse model of polycystic kidney disease. In addition, Zhou et al. [12] reported the ameliorative effects of paclitaxel on liver fibrosis.

In this study, we tried to determine whether taurine and Taxol can attenuate the tubulointerstitial fibrosis and preserve the normal renal histology in a rat model of UUO. Moreover, stereological survey was applied to investigate structural changes in the uropathic kidney, including the volume of the cortex, medulla, glomeruli, proximal convoluted tubules (PCT), distal convoluted tubules (DCT), Henle tubules, collecting ducts, vessels, and fibrous tissue. In addition, the length of the tubules and the vessels was estimated. These methods provide both quantitative and comparative data.

MATERIALS AND METHODS

1. Animals
Twenty-four male rats weighing 160±30 g were selected. The animals were treated according to the standard directive as recommended and approved by the research authorities of Shiraz University of Medical Sciences. The rats were randomly divided into four groups each including six animals, which is considered acceptable for stereological studies [13]. In group one ( sham-operated animals), laparotomy only was done without any procedures and the rats did not receive any treatments. On the other hand, groups two, three, and four underwent a surgery to induce UUO. The second group received distilled water by gavage. The third group received Taxol (0.3 mg/kg twice per week intraperitoneally) for 28 days [8]. Finally, the fourth group was treated with taurine (7.5 mg/kg/d) dissolved in a distilled water vehicle given by gavage for 28 days [9].

2. Surgical procedure
After the rats were anesthetized with ketamine/xylosine (25 mg/kg i.p. and 2.5 mg/kg i.p., respectively), the abdominal cavity was opened by an incision to reach the left ureter. A 3-0 silk ligature was tied around the ureter, after which the incision was closed. After 28 days, the rats’ kidneys were removed.

3. Stereological study
The renal pelvis was dissected out and the kidney was weighed. The primary volume of the kidney, \(V_{\text{primary}}\), was measured by using Sherle’s immersion method [14]. A brief description is presented under Fig. 1. The kidney was fixed in neutral buffered formaldehyde for 1 week. Then, the tissue shrinkage produced by fixation, processing, and staining was estimated. Estimation of the shrinkage and the length of the renal tubules as well as the vessels requires isotropic, uniform random sections [15-17]. These sections were obtained through the orientator method. A brief description is presented under Fig. 2. The estimated shrinkage was also used to estimate the final volume of the kidney to avoid the consecutive sectioning that is required for the Cavalieri method. A description can be found under Fig. 3. After estimating the volume shrinkage [15-17], the final volume of the kidney (the reference space) was corrected by using the following formula:

\[
V_{\text{final}} = V_{\text{primary}} \times (1 - \text{volume shrinkage}).
\]

4. Estimation of the volume and length densities
Each sampled section was analyzed by using a video microscopy system that was made up of a microscope (E-200,
Isotropic uniform random sectioning by use of the orientator method. (A) The kidney was cleaned. (B) It was placed on the circle such that each half of it was divided into 10 equal parts. A random number between 0 and 9 was selected. The kidney was sectioned into two parts at the direction of the selected number (here 4). (C) The cut surface of one part of the kidney was, then, placed on the 0-0 direction of the second circle with 10 unequal divisions. The circle division was done according to the cosine of the angels. Then, another random number was selected and the second cut was done (here 1). The parts were sectioned into parallel slabs. (D) The cut surface of the other part of the kidney was placed vertically on the second circle. Again, a new number and direction (here 6) was selected and cut. This part was also sectioned into parallel slabs.

Estimation of shrinkage and slide preparation. (A) The entire kidney was sectioned into slabs with a blade and was placed in the direction of the isotropic uniform random cut with an interval of 0.5 mm. Then, the slabs (8 to 12 slabs) were collected. A circle (left arrow) was punched from a kidney slab (right arrow) by a trocar. The diameter of the circular piece and the area of the circle were estimated using the usual formula for calculating the area of a circle. (B) The cut surface of the slabs and the circle were embedded in the paraffin block. (C) Sectioning of the block using the microtome blade (5 μm thicknesses) is demonstrated. After staining with Heidenhain’s Azan trichrome, the area of the circular piece was measured again and the volume shrinkage was calculated by using the following formula: volume shrinkage \(=1-(AA/AB)^{1.5}\), where \(AA\) and \(AB\), respectively, represent the area of the circular piece after and before the processing, the sectioning, and the staining. After estimating the shrinkage, the final volume of the kidney (the reference space) was computed by using the following formula: \(V_{\text{final}}=V_{\text{primary}}(1-\text{volume shrinkage})\). (D) The microscopic fields were sampled in a systematic random design. The fields were sampled and analyzed at equal intervals along the X- and Y-axis by using a stage micrometer. This procedure was continued until all the sections had been studied.

The volume density of each structure (the fraction of the unit volume of the kidney that is occupied by the structure) was estimated by using the point-counting method. A brief description is presented under Fig. 4. The volume fraction of the cortex and the medulla were estimated at a final magnification of x375 and other parameters at x1,500. The length density (the length of each tubular structure in the unit volume of the kidney) of the proximal and the DCT, collecting ducts, Henle’s loop, and vessels was estimated by randomly overlaying an unbiased counting frame [15] with an area of 2,700 μm² on the live monitor images. A brief description is presented as the legend of Fig. 5.

Finally, the total volume of the parameters and the total length of the tubules as well as the vessels were estimated by multiplying the fractional volume or the length density by the final volume of the kidney to prevent the “reference trap” [15-17].

5. Statistical analysis
The data are reported as means and Standard deviations. Statistical comparisons between the group means were done by Kruskall-Wallis and Mann-Whitney U-test.
The volume density estimation using the point-counting method. A gird of points was superimposed upon the images of the renal sections viewed on the monitor. The volume density (fractional volume) \((V_v)\) of the renal cortex, the medulla, the glomeruli, the proximal convoluted tubules, the distal convoluted tubule, the collecting ducts, the Henle’s loop, the vessels, and the connective tissue was obtained by using the point-counting method and the following formula:

\[
V_v = \frac{P_{\text{structure}}}{P_{\text{total}}}
\]

where \(P_{\text{structure}}\) and \(P_{\text{total}}\) represent the sum of the number of the points hitting the structure and all sampled fields of the kidney, respectively. The point is the right upper corner of the cross (the arrow) (Heidenhain’s AZAN trichrome stain, x200).

The length density estimation in a kidney with an obstructed ureter. The counting frame with exclusion lines (bold lines of the left and lower borders) and inclusion lines (thin lines of the right and upper borders) was superimposed on the images. The tubules that were either completely or partly inside the counting frame and did not touch the exclusion lines were counted. The length density \((L_v)\) of each tubule was calculated by using the following formula:

\[
L_v = 2 \sum Q / \sum A_T
\]

where \(\Sigma Q\) denotes the total number of each tubule profiles counted per kidney and \(A_T\) was the test area that was calculated by multiplying the area of the frame (here was 2,700 \(\mu m^2\)) and the total number of the counted frames (Heidenhain’s AZAN trichrome stain, x400).

Moreover, \(p \leq 0.01\) was considered as statistically significant.

RESULTS

1. Histopathological changes

The histological changes of the kidney after the UUO procedure as well as after the UUO procedure plus Taxol or taurine treatment can be observed in Fig. 6. Renal disruption, tubular atrophy, degeneration, necrosis, and fibrosis were observed in the UUO animals. After treatment with Taxol or taurine, the histopathological changes were ameliorated such that more tubules remained identifiable. The amount of fibrotic and necrotic tissue decreased after treatment with Taxol or taurine. Furthermore, the UUO rats treated with Taxol showed more intact renal structures.

2. Volume of the kidney structures

The mean and the standard deviation of the kidney volume, the volume of the cortex, and the volume of the medulla are presented in Table 1. No significant differences were observed between the groups.

The total volume of the glomeruli, PCT, DCT, Henle’s loop, collecting duct, degenerative tubules, and necrotic and fibrotic tissue in the different groups is shown in Table 2. The volume of the glomeruli, PCT, DCT, Henle’s loop, and collecting ducts was reduced in the rats after UUO. Less than -8% of these structures remained intact on average.

After treatment of the UUO rats with Taxol, -87%, -32%, -51%, -72%, and -88% of the glomeruli, PCT, DCT, Henle’s loop, and collecting ducts remained intact, respectively \((p < 0.01)\).

After treatment of the UUO rats with taurine, -25%, -16%, -16%, -40%, and -46% of the glomeruli, PCT, DCT, Henle’s loop, and collecting ducts remained intact, respectively \((p < 0.01)\).

Table 2 depicts the increase in degenerative tubules and necrotic and fibrotic tissues in the UUO groups. In addition, after treating the UUO animals with Taxol, the volume of the degenerative tubules and necrotic and fibrotic tissues was decreased -42% and -53%, respectively, compared with that in the UUO rats.

After treating the UUO rats with taurine, the volume of the degenerative tubules increased 1.8-fold, whereas necrotic and fibrotic tissues decreased -63% compared with that in the UUO rats without any treatments \((p < 0.01)\).

3. Length of the tubular structures of the kidney

On average, less than -3% of the lengths of these structures remained intact in the UUO rats. After treatment of the UUO rats with Taxol, -65%, 70%, 56%, and 61% of the PCT, DCT, Henle’s loop, and collecting ducts remained intact, respectively \((p < 0.01)\).

On the other hand, after treatment of the UUO rats with taurine, -49%, -53%, -43%, and -45%, of the length of the PCT, DCT, Henle’s loop, and collecting ducts remained in-
TABLE 1. Comparison of weight and volume among the groups

| Group | No. of rats | Animal weight (g) | Kidney weight (mg) | Kidney volume (mm³) | Cortex volume (mm³) | Medulla volume (mm³) |
|-------|-------------|------------------|-------------------|-------------------|-------------------|-------------------|
| 1a    | 6           | 180±16           | 536±42            | 352±40            | 196±30            | 155±14            |
| 2b    | 6           | 169±13           | 538±63            | 336±23            | 181±18            | 152±15            |
| 3c    | 6           | 165±13           | 598±104           | 320±45            | 166±26            | 153±20            |
| 4d    | 6           | 163±9            | 484±47            | 302±53            | 159±26            | 142±27            |

Values are presented as mean±standard deviation.

a: Sham-operated animals in which laparotomy was done without any procedure and no treatment was given, b: animals underwent a surgery to induce unilateral ureteral obstruction, c: animals underwent a surgery to induce unilateral ureteral obstruction and received taxol (0.3 mg/kg twice per week intraperitoneally) for 28 days, d: animals underwent a surgery to induce unilateral ureteral obstruction and received taurine (7.5 mg/kg/d) given by the gavage for 28 days.

FIG. 6. A comparison of the renal tissue in different groups. (A) The normal tissue. (B) The renal tissue after the unilateral ureteral obstruction (UUO). (C) The renal tissue after the UUO+taxol. (D) The renal tissue after the UUO+taurine (Heidenhain’s AZAN trichrome stain, x200).

DISCUSSION

The present study confirmed through a quantitative survey the protective role of Taxol and taurine on renal tissue damage after the induction of UUO in rats. Furthermore, the findings of the present study revealed that Taxol was more protective than taurine. Paclitaxel is an alkaloid plant that is derived from the bark of the Pacific yew tree.
Paclitaxel works by disrupting the microtubular network essential for cell division and other normal cellular functions, which eventually leads to cell death [12]. The positive effects of Taxol have been reported in cisplatin-induced and ischemia-reperfusion injuries [18,19]. Moreover, a study demonstrated that Taxol can attenuate oxidative/nitrosative stress, glutathione depletion, enhanced urinary hydrogen peroxide excretion, and the decrease in antioxidant enzymes (catalase, glutathione peroxidase, and glutathione-S-transferase) [18]. In addition, Yoon et al. [18] reported that Taxol can induce cytoprotective enzymes and thereby improve the ischemia-reperfusion-induced changes in lipid hydroperoxides, glutathione, creatinine clearance, kidney weight, and histological abnormalities.

The other compound that was used in the present study was taurine. The protective effect of taurine on nephrotoxicity after cyclosporine or cisplatin treatment has been reported [9]. It is believed that taurine, owing to its antioxidant properties, avoids cyclosporine-induced reactive oxygen species and, consequently, nephrotoxicity [20,21]. In a recent article by Yousef et al. [22], it was shown that taurine induces a protective property after paracetamol-induced oxidative injury of the kidney. Articles have discussed various mechanisms by which Taxol and taurine may protect renal structure changes after UUO. For example, the results of a study by Sun et al. [9] revealed that a low dose of paclitaxel ameliorates renal fibrosis via the modulation of microRNA-192 pathobiology and transforming growth factor-\( \beta \) signaling [10]. Transforming growth factor-\( \beta \) has been shown to play a central role in the development of the tubulointerstitial fibrosis. Guerrero-Beltran et al. [23] reported that Taxol can prevent cell death and inflammation in nephropathy. The antifibrotic effects of Taxol have been observed in other tissues including the liver. The findings of the study by Zhou et al. [12] indicate that 200 nmol/l paclitaxel ameliorates hepatic fibrosis by modulating transforming growth factor-beta signaling. In addition, Koz et al. [24] showed that paclitaxel provided antifibrotic effects during conjunctival wound healing.

The role of taurine in various renal structures has also been reviewed [2]. These major roles include regulating the blood flow in the vasculature of the kidney, scavenging the reactive oxygen species in glomerulus, Na\(^+\) transport in the proximal tubules, and osmoregulation as well as cell volume regulation in the medulla. In addition to the pre-

---

**Table 2. Comparison of the volume of the renal structures in the groups**

| Group | No. of rats | Glomeruli (mm\(^3\)) | PCT (mm\(^3\)) | DCT (mm\(^3\)) | Henle’s loop (mm\(^3\)) | Collecting ducts (mm\(^3\)) | Degenerative tubules (mm\(^3\)) | Necrotic & fibrotic tissues (mm\(^3\)) |
|-------|-------------|-----------------------|----------------|----------------|---------------------|------------------------|-------------------------------|----------------------------------|
| 1\(^a\) | 6           | 16±6                  | 192±37         | 43±9           | 25±12               | 26±7                   | 1±1                           | 1±1                              |
| 2\(^b\) | 6           | 1±1                   | 1±1            | 1±1            | 1±1                 | 2±2                    | 21±7                          | 309±23                           |
| 3\(^c\) | 6           | 14±7\(^f\)            | 63±18\(^f\)    | 22±3\(^f\)     | 18±6                | 23±4\(^f\)             | 9±9\(^f\)                     | 165±24                           |
| 4\(^d\) | 6           | 4±3                   | 32±5           | 7±6            | 10±7                | 12±4                   | 37±12                         | 197±42                           |

Values are presented as mean±standard deviation. PCT, proximal convoluted tubule; DCT, distal convoluted tubule.

\( ^a \): Sham-operated animals in which laparotomy was done without any procedure and no treatment was given, \( ^b \): animals underwent a surgery to induce unilateral ureteral obstruction, \( ^c \): animals underwent a surgery to induce unilateral ureteral obstruction and received taxol (0.3 mg/kg twice per week intraperitoneally) for 28 days, \( ^d \): animals underwent a surgery to induce unilateral ureteral obstruction and received taurine (7.5 mg/kg/d) given by gavage for 28 days, \( ^f \): \( p < 0.01 \), group 2 vs. (group 3) or (group 4), \( ^f \): \( p < 0.01 \), (group 3) vs. (group 4).

**Table 3. Comparison of the length of renal tubular structures in the groups**

| Group | No. of rats | Proximal distal convoluted tubules (m) | DCT (m) | Henle’s loop (m) | Collecting duct (m) | Vessels (m) |
|-------|-------------|----------------------------------------|---------|------------------|---------------------|-------------|
| 1\(^a\) | 6           | 87±3                                   | 64±9    | 39±9             | 55±5               | 44±1        |
| 2\(^b\) | 6           | 1±1\(^e\)                             | 1±1\(^e\) | 1±1\(^e\)       | 1±1\(^e\)         | 1±1\(^e\)  |
| 3\(^c\) | 6           | 57±11\(^f\)                           | 45±9\(^f\) | 22±4\(^f\)     | 34±6\(^f\)        | 17±6        |
| 4\(^d\) | 6           | 43±7                                   | 34±6    | 17±3             | 25±4               | 14±3        |

Values are presented as mean±standard deviation. PCT, proximal convoluted tubule; DCT, distal convoluted tubule. **Group 2** vs. (group 3) or (group 4), \( ^f \): \( p < 0.01 \), (group 3) vs. (group 4).
ventive roles of taurine in renal fibrosis, other tissues can also be protected. Devi et al. [25] reported that taurine reduces iron-potentiated alcoholic liver fibrosis by reducing oxidative stress, inflammatory and fibrogenic mediators, and stellate cell activation. In addition, the results of the study by Devi and Anuradha [26] showed that the restorative effect of taurine in an experimental model of liver fibrosis involved amelioration of protein and lipid damage by decreasing oxidative and nitrosative stresses. Therefore, variety of mechanisms can be considered responsible for the protective effects of Taxol and taurine in the present study.

CONCLUSIONS

It can be concluded that Taxol and taurine are both effective in preventing some structural renal damage in the direct obstruction model in rats. The volume of the necrotic and fibrotic tissue was found to be less in the Taxol- and taurine-treated groups. Furthermore, taurine revealed a more protective role on renal structures.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

ACKNOWLEDGEMENTS

The present research was carried out at the Histomorphometry & Stereology Research Center of Shiraz University of Medical Sciences. The authors would like to thank Dr. Ali Musavi as well as Mr. Hashem Zare as the software providers. They also would like to thank Miss. Elham Nadimi, Miss. Zahra Keshavarz, and Mr. Mehrdad Azadi for their technical assistance. The Research Improvement Center of Shiraz University of Medical Sciences and Ms. Afsaneh Keivanshekouh are also appreciated for improving the use of English in the manuscript.

REFERENCES

1. Sato S, Yamate J, Saito T, Hosokawa T, Saito S, Kurasaki M. Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin. Naunyn Schmiedebergs Arch Pharmacol 2002;365:277-83.
2. Chesney RW, Han X, Patters AB. Taurine and the renal system. J Biomed Sci 2010;17 Suppl 1:S4.
3. Trachtman H, Futterweit S, Maesaka J, Ma C, Valderrama E, Fuchs A, et al. Taurine ameliorates chronic streptozocin-induced diabetic nephropyathy in rats. Am J Physiol 1995;269:F122-9.
4. Cruz CI, Ruiz-Torres P, del Moral RG, Rodriguez-Puyol M, Rodriguez-Puyol D. Age-related progressive renal fibrosis in rats and its prevention with ACE inhibitors and taurine. Am J Physiol Renal Physiol 2000;278:F122-9.
5. Marcinikiewicz J, Kurnyta M, Biedron R, Bobek M, Kontry E, Maslinski W. Anti-inflammatory effects of taurine derivatives (taurine chloramine, taurine bromamine, and taurolidine) are mediated by different mechanisms. Adv Exp Med Biol 2006;583:481-92.
6. Odobasic D, Kitching AR, Semple TJ, Holdsworth SR. Endogenous myeloperoxidase promotes neutrophil-mediated renal injury, but attenuates T cell immunity inducing crescentic glomerulonephritis. J Am Soc Nephrol 2007;18:760-70.
7. Suliman ME, Barany P, Filho JC, Lindholm B, Bergstrom J. Accumulation of taurine in patients with renal failure. Nephrol Dial Transplant 2002;17:528-9.
8. Erdem A, Gundogan NU, Usubutun A, Kiliç K, Erdem SR, Kara A, et al. The protective effect of taurine against gentamicin-induced acute tubular necrosis in rats. Nephrol Dial Transplant 2000;15:1175-82.
9. Sun L, Zhang D, Liu F, Xiang X, Ling G, Xiao L, et al. Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J Pathol 2011;225:364-77.
10. Zhang D, Sun L, Xian W, Liu F, Ling G, Xiao L, et al. Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity. Lab Invest 2010;90:436-47.
11. Sommardahl CS, Wojchik RP, Sweeney WE, Avernd EL, Wilkinson JE. Efficacy of taurine in the orpk mouse model of polycystic kidney disease. Pediatr Nephrol 1997;11:728-33.
12. Zhou J, Zhong DW, Wang QW, Miao XY, Xu XD. Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activity. World J Gastroenterol 2010;16:3330-4.
13. Hyde DM, Tyler NK, Flopper CC. Morphometry of the respiratory tract: avoiding the sampling, size, orientation, and reference traps. Toxicol Pathol 2007;35:41-8.
14. Scherle W. A simple method for volumetry of organs in quantitative stereology. Mikroskopie 1970;26:57-60.
15. Nyengard JR. Stereologic methods and their application in kidney research. J Am Soc Nephrol 1999;10:1100-23.
16. Gundersen HJ, Bendtsen TF, Koro L, Marcussen N, Moller A, Nielsen K, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APNIS 1988;96:379-94.
17. Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Koro L, Marcussen N, et al. The new stereological tools: dissector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APNIS 1988;96:857-81.
18. Yoon HY, Kang NI, Lee HK, Jang KY, Park JW, Park BH. Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem Pharmacol 2008;75:2214-23.
19. Guerrero-Beltran CE, Calderon- Oliver M, Tapia E, Medina-Campos ON, Sanchez-Gonzalez DJ, Martinez-Martinez CM, et al. Sulforaphane protects against cisplatin-induced nephrotoxicity. Toxicol Lett 2010;192:278-85.
20. Mostafavi-Pour Z, Tal F, Manabati A, Vessal M. Protective effects of a combination of quercetin and vitamin E against cyclosporine A-induced oxidative stress and hepatotoxicity in rats. Hepatol Res 2008;38:385-92.
21. Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Perez-Barriocanal F, Morales AI, Lopez-Novoa JM. Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity. Nephrol Dial Transplant 2011;26:3484-95.
22. Yousef MI, Omar SA, el-Guendi MI, Abdelmegid LA. Potential protective effects of quercetin and curcumin on paracetamol-induced histological changes, oxidative stress, impaired liver and kidney functions and haematoxicity in rats. Food Chem Toxicol 2010;48:3246-61.
23. Guerrero-Beltran CE, Mukhopadhyay P, Horvath B, Rashid M, Tapia E, Garcia-Torres I, et al. Sulforaphane, a natural constituent of broccoli, prevents cell death and inflammation in...
24. Koo OG, Ozhuy S, Tezel GG, Karaman N, Unlu N, Yarangumeli A, et al. The effect of paclitaxel on conjunctival wound healing: a pilot study. J Glaucoma 2007;16:610-5.

25. Devi SL, Viswanathan P, Anuradha CV. Regression of liver fibrosis by taurine in rats fed alcohol: effects on collagen accumulation, selected cytokines and stellate cell activation. Eur J Pharmacol 2010;647:161-70.

26. Devi SL, Anuradha CV. Oxidative and nitrosative stress in experimental rat liver fibrosis: Protective effect of taurine. Environ Toxicol Pharmacol 2010;29:104-10.